SCHEMBL4373922

SCHEMBL4373922

COc1ccc(C2CNC(=CC(=O)O)C2)cc1OC1CCCC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 17/20 0.71
PDE4A P27815 13/20 0.71
PDE4C Q08493 10/20 0.71
PDE4D Q08499 10/20 0.71
CYP3A4 P08684 2/20 0.71
VEGFA P15692 1/20 0.71
ALDH1A1 P00352 1/20 0.71
LMNA P02545 1/20 0.71
CYP1A2 P05177 1/20 0.71
MAPT P10636 1/20 0.71
CYP2C9 P11712 1/20 0.71
ALOX15 P16050 1/20 0.71
CREBBP Q92793 1/20 0.71
KDM4E B2RXH2 1/20 0.71
PDE5A O76074 1/20 0.71
TNF P01375 1/20 0.71
MAPK1 P28482 1/20 0.71
BLM P54132 1/20 0.71
PDE1A P54750 1/20 0.71
PDE1B Q01064 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28332849 1.00 PDE4B (0.71) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL4373919 1.00 PDE4B (0.71) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL28332840 1.00 PDE4B (0.71) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL28352179 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL6053887 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL6053885 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL29623773 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL29623500 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
SCHEMBL1134133 0.87 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DCYP3A4
S-Rolipram SCHEMBL5321568 0.83 PDE4A (1.00) PDE4BPDE4APDE4CPDE4DCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305329-B2 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT GLAXO GROUP LTD (GB) 2015-03-18 EP claimed
EP-1305329-B1 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT GLAXO GROUP LTD (GB) 2007-12-05 EP claimed
CN-106279110-B heterocyclic compounds, medicaments containing said compounds, their use and processes for their preparation 勃林格殷格翰国际有限公司 2019-12-10 CN disclosed
EP-2091571-A2 METHOD FOR STERILIZING A FILM CONTAINER Boehringer Ingelheim International GmbH (DE) 2009-08-26 EP disclosed
WO-2008049915-A2 METHOD FOR STERILIZING A FILM CONTAINER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-02 WO disclosed
EP-1896026-A2 PROCESS FOR PREPARING TIOTROPIUM SALTS, TIOTROPIUM SALTS AS SUCH AND PHARMACEUTICAL COMPOSITIONS THEREOF Boehringer Ingelheim International GmbH (DE) 2008-03-12 EP disclosed
WO-2006134021-A2 PROCESS FOR PREPARING TIOTROPIUM SALTS, TIOTROPIUM SALTS AS SUCH AND PHARMACEUTICAL COMPOSITIONS THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-12-21 WO disclosed
US-20060035877-A1 Method and compositions for treating pulmonary diseases GOODFELLOW PETER N 2006-02-16 US disclosed
US-20040028615-A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) 2004-02-12 US disclosed
WO-2003048181-A1 17.ALPHA. -CYCLIC ESTERS OF 16-METHYLPREGNAN-3,20-DIONE AS ANTI-INFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040028615-A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents HSD17B1, HSD17B7, HSD3B1 PDE4B 3401/4885PDE4A 2770/4885PDE4C 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.